Celldex Therapeutics, Inc. (CLDX) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 15 Buy, 3 Hold, 1 Sell.
The consensus price target is $24.00, representing a downside of 28% from the current price $33.33.
Analysts estimate Earnings Per Share (EPS) of $-2.48 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.45 vs est $-2.48 (beat +1%). 2025: actual $-3.90 vs est $-3.71 (missed -5.1%). Analyst accuracy: 97%.
CLDX Stock — 12-Month Price Forecast
$24.00
▼ -27.99% Downside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Celldex Therapeutics, Inc., the price target is $24.00.
The average price target represents a -27.99% change from the last price of $33.33.
CLDX Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Celldex Therapeutics, Inc. in the past 3 months
EPS Estimates — CLDX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.45
vs Est –$2.48
▲ 1.0% off
2025
Actual –$3.90
vs Est –$3.71
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CLDX
58%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.007B
vs Est $0.007B
▲ 2.2% off
2025
Actual $0.002B
vs Est $0.003B
▼ 81.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
